Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 5839: Exome sequencing revealed comparable frequencies of RNF43 mutations and BRAF mutations in Middle Eastern colorectal cancer

View through CrossRef
Abstract Mutation-induced activation of Wnt-β Catenin signaling is a frequent event in CRC. The E3 ubiquitin ligase, RNF43, has been reported to negatively regulate the Wnt signaling pathway. Although, RNF43 mutations are frequently seen in CRC, its role in CRC from Middle Eastern ethnicity remains unclear. Therefore, we conducted this study to assess the frequency of RNF43 mutations, the clinico-pathological and molecular associations in two independent cohorts of Middle Eastern CRC. Exome sequencing was utilized to identify the somatic mutations in RNF43 gene and in known CRC driver genes including APC, TP53, KRAS, BRAF and NRAS among 113 CRC cases of discovery cohort. In validation cohort of 107 CRC cases, Sanger sequencing was employed to detect the mutations in exon 2, 4, 8 and 9 in RNF43 gene while Targeted capture sequencing was conducted to identify the mutations in entire region of APC gene and hotspot regions of KRAS, BRAF, NRAS and TP53 genes. RNF43 somatic mutations were found in 5.9% (13/220) of the entire CRC cohort, which is similar in frequency to BRAF mutations, which were identified in 3.6% (8/220). The mutations in other known driver genes including APC, TP53, KRAS and NRAS were observed in 58.2% (128/220), 50.9% (112/220), 46.4% (102/220) and 2.7% (6/220) cases, respectively, in all 220 tumors examined. However, no significant association between RNF43 mutations and BRAF mutations was seen. RNF43 was found to be inversely correlated to APC and TP53 mutations. Clinico-pathological analysis showed a strong association of RNF43 mutations with right sided and sporadic deficient mismatch repair (dMMR) CRC. No association was identified between RNF43 mutation and other clinico-pathological features such as age, tumor histological subtype, tumor grade or patients’ prognosis. Multivariate logistic regression analysis revealed that dMMR status (Odds ratio = 5.43; 95% confidence interval = 1.12 - 26.32; p = 0.0356) and wild type APC (Odds ratio = 4.77; 95% confidence interval = 1.51 - 19.77; p = 0.0312) were independent predictors of RNF43 mutation. Our results revealed that RNF43 mutations do occur in CRC from Middle Eastern ethnicity at comparable frequencies with BRAF mutations and represent a distinct molecular subtype which further enhance our understanding of how different mutational subsets of Wnt tumor suppressor genes link to distinct tumor characteristics, which might be considered for treatment strategies for CRC patients. Citation Format: Rong Bu, Abdul K. Siraj, Tariq Masoodi, Sandeep Kumar Parvathareddy, Kaleem Iqbal, Allianah D. Benito, Sarah Siraj, Nabil Siraj, Maha Al Rasheed, Saeeda O. Ahmed, Wael AL-Haqaw, Maria Angelita Sabido, Mark Ranier Diaz, Padmanaban Annaiyappanaidu, Khawla S. Al-Kuraya. Exome sequencing revealed comparable frequencies of RNF43 mutations and BRAF mutations in Middle Eastern colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5839.
Title: Abstract 5839: Exome sequencing revealed comparable frequencies of RNF43 mutations and BRAF mutations in Middle Eastern colorectal cancer
Description:
Abstract Mutation-induced activation of Wnt-β Catenin signaling is a frequent event in CRC.
The E3 ubiquitin ligase, RNF43, has been reported to negatively regulate the Wnt signaling pathway.
Although, RNF43 mutations are frequently seen in CRC, its role in CRC from Middle Eastern ethnicity remains unclear.
Therefore, we conducted this study to assess the frequency of RNF43 mutations, the clinico-pathological and molecular associations in two independent cohorts of Middle Eastern CRC.
Exome sequencing was utilized to identify the somatic mutations in RNF43 gene and in known CRC driver genes including APC, TP53, KRAS, BRAF and NRAS among 113 CRC cases of discovery cohort.
In validation cohort of 107 CRC cases, Sanger sequencing was employed to detect the mutations in exon 2, 4, 8 and 9 in RNF43 gene while Targeted capture sequencing was conducted to identify the mutations in entire region of APC gene and hotspot regions of KRAS, BRAF, NRAS and TP53 genes.
RNF43 somatic mutations were found in 5.
9% (13/220) of the entire CRC cohort, which is similar in frequency to BRAF mutations, which were identified in 3.
6% (8/220).
The mutations in other known driver genes including APC, TP53, KRAS and NRAS were observed in 58.
2% (128/220), 50.
9% (112/220), 46.
4% (102/220) and 2.
7% (6/220) cases, respectively, in all 220 tumors examined.
However, no significant association between RNF43 mutations and BRAF mutations was seen.
RNF43 was found to be inversely correlated to APC and TP53 mutations.
Clinico-pathological analysis showed a strong association of RNF43 mutations with right sided and sporadic deficient mismatch repair (dMMR) CRC.
No association was identified between RNF43 mutation and other clinico-pathological features such as age, tumor histological subtype, tumor grade or patients’ prognosis.
Multivariate logistic regression analysis revealed that dMMR status (Odds ratio = 5.
43; 95% confidence interval = 1.
12 - 26.
32; p = 0.
0356) and wild type APC (Odds ratio = 4.
77; 95% confidence interval = 1.
51 - 19.
77; p = 0.
0312) were independent predictors of RNF43 mutation.
Our results revealed that RNF43 mutations do occur in CRC from Middle Eastern ethnicity at comparable frequencies with BRAF mutations and represent a distinct molecular subtype which further enhance our understanding of how different mutational subsets of Wnt tumor suppressor genes link to distinct tumor characteristics, which might be considered for treatment strategies for CRC patients.
Citation Format: Rong Bu, Abdul K.
Siraj, Tariq Masoodi, Sandeep Kumar Parvathareddy, Kaleem Iqbal, Allianah D.
Benito, Sarah Siraj, Nabil Siraj, Maha Al Rasheed, Saeeda O.
Ahmed, Wael AL-Haqaw, Maria Angelita Sabido, Mark Ranier Diaz, Padmanaban Annaiyappanaidu, Khawla S.
Al-Kuraya.
Exome sequencing revealed comparable frequencies of RNF43 mutations and BRAF mutations in Middle Eastern colorectal cancer [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13.
Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5839.

Related Results

Abstract 1448: Unraveling the oncogenic pathway of serrated polyposis syndrome driven by RNF43 germline mutation
Abstract 1448: Unraveling the oncogenic pathway of serrated polyposis syndrome driven by RNF43 germline mutation
Abstract Serrated polyps can arise in a sporadic or familial polyposis setting and predispose to colorectal cancer (CRC). Recently, we have identified RNF43 germline...
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
<div>Abstract<p>One of the most encouraging developments in oncology has been the success of BRAF inhibitors in <i>BRAF</i>-mutant melanoma. However, in con...
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
<div>Abstract<p>One of the most encouraging developments in oncology has been the success of BRAF inhibitors in <i>BRAF</i>-mutant melanoma. However, in con...
Genomic profiles of BRAF inhibitor resistance mechanisms in metastatic colorectal cancer.
Genomic profiles of BRAF inhibitor resistance mechanisms in metastatic colorectal cancer.
e15527 Background: BRAF mutations are present in 5-10% of metastatic colorectal cancers (mCRCs). Patients with mCRC whose tumors harbor BRAF V600 mutation generally respond poorly...
Tracking emerging KRAS, BRAF and EGFR mutations through ccfDNA in colorectal cancers treated with EGFR blockade.
Tracking emerging KRAS, BRAF and EGFR mutations through ccfDNA in colorectal cancers treated with EGFR blockade.
547 Background: Epidermal growth factor receptor (EGFR) blockade can achieve considerable tumor shrinkage in patients with metastatic colorectal cancer (CRC). However, most patien...
A DNA repair player, ring finger protein 43, relieves etoposide‐induced topoisomerase II poisoning
A DNA repair player, ring finger protein 43, relieves etoposide‐induced topoisomerase II poisoning
AbstractRing finger protein 43 (RNF43) is an E3 ubiquitin ligase which is well‐known for its role in negative regulation of the Wnt‐signaling pathway. However, the function in DNA ...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...

Back to Top